← Leaderboards
Jeyarama Ananta
Nirmidas Biotech, Inc.
$707,549
Attributed
$918,405
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $725.8K · FY2017–18$1M$750K$500K$250K$0
'17
'18
Funding mix
By agency
NIH$918,405 · 2
By mechanism
R44$496,692 · 1
R21$421,713 · 1
Top collaborators
- Benjamin Pinsky2 shared
Most similar at Nirmidas Biotech, Inc.
Same institution · by research overlap
- Joshua Tucker Robinson$206,973
- Lynn Kozma$804,811
Others in their field
Other Emerging Leaders on “Sampling”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,167,581
- Beth Baseler · Leidos Biomedical Research, Inc.$105,136,677
- Scott Topper · Broad Institute, Inc.$77,958,806
- Paul F Gallagher · Woods Hole Oceanographic Institution$63,916,876
- Leonard Freedman · Leidos Biomedical Research, Inc.$60,323,945
- Dale Sandler · Social And Scientific Systems, Inc.$59,740,435
Research focus
SamplingSpecificityEnzyme-Linked Immunosorbent AssayPlasmonicsSerumSignal TransductionDetectionEarly DiagnosisImmunoglobulin GNanotechnologySensitivity And SpecificityBaseAntibodiesBiological MarkersBiotechnologyAntigensDiagnosisDiagnosticFluorescenceGoldChildInsulin-Dependent Diabetes MellitusScreeningBinding
Grant awards (3)
A Nanoscale Plasmonic-Gold Platform for Specific Diagnosis of Zika and Differentiation from other Flavivirus Infections$192,600
R21 · FY2018 · AI · contact PI
Development of multiplexed autoantibody test on pGOLD platform for Diagnosis and Screening of Type 1 Diabetes$496,692
R44 · FY2017 · DK · contact PI
A Nanoscale Plasmonic-Gold Platform for Specific Diagnosis of Zika and Differentiation from other Flavivirus Infections$229,113
R21 · FY2017 · AI · contact PI